- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-S29A1/ SLC29A1/ ENT1 monoclonal antibody
Anti-S29A1/ SLC29A1/ ENT1 antibody for FACS & in-vivo assay
Go to SLC29A1/SLC29A1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T13491-Ab-1/ GM-Tg-hg-T13491-Ab-2 | Anti-Human SLC29A1 monoclonal antibody | Human |
| GM-Tg-rg-T13491-Ab-1/ GM-Tg-rg-T13491-Ab-2 | Anti-Rat SLC29A1 monoclonal antibody | Rat |
| GM-Tg-mg-T13491-Ab-1/ GM-Tg-mg-T13491-Ab-2 | Anti-Mouse SLC29A1 monoclonal antibody | Mouse |
| GM-Tg-cynog-T13491-Ab-1/ GM-Tg-cynog-T13491-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SLC29A1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T13491-Ab-1/ GM-Tg-felg-T13491-Ab-2 | Anti-Feline SLC29A1 monoclonal antibody | Feline |
| GM-Tg-cang-T13491-Ab-1/ GM-Tg-cang-T13491-Ab-2 | Anti-Canine SLC29A1 monoclonal antibody | Canine |
| GM-Tg-bovg-T13491-Ab-1/ GM-Tg-bovg-T13491-Ab-2 | Anti-Bovine SLC29A1 monoclonal antibody | Bovine |
| GM-Tg-equg-T13491-Ab-1/ GM-Tg-equg-T13491-Ab-2 | Anti-Equine SLC29A1 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T13491-Ab-1/ GM-Tg-hg-T13491-Ab-2; GM-Tg-rg-T13491-Ab-1/ GM-Tg-rg-T13491-Ab-2; GM-Tg-mg-T13491-Ab-1/ GM-Tg-mg-T13491-Ab-2; GM-Tg-cynog-T13491-Ab-1/ GM-Tg-cynog-T13491-Ab-2; GM-Tg-felg-T13491-Ab-1/ GM-Tg-felg-T13491-Ab-2; GM-Tg-cang-T13491-Ab-1/ GM-Tg-cang-T13491-Ab-2; GM-Tg-bovg-T13491-Ab-1/ GM-Tg-bovg-T13491-Ab-2; GM-Tg-equg-T13491-Ab-1/ GM-Tg-equg-T13491-Ab-2 |
| Products Name | Anti-SLC29A1 monoclonal antibody |
| Format | mab |
| Target Name | SLC29A1 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-SLC29A1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Figure. >95% purity by SDS-PAGE under reduced conditions, 98.854% purity by SEC-HPLC test.
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species S29A1/ SLC29A1/ ENT1 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | pGMLPm003776 | mouse Slc29a1 Lentivirus plasmid |
| ORF Viral Vector | pGMLPm003777 | mouse Slc29a1 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm003776 | mouse Slc29a1 Lentivirus particle |
| ORF Viral Vector | vGMLPm003777 | mouse Slc29a1 Lentivirus particle |
Target information
| Target ID | GM-T13491 |
| Target Name | SLC29A1 |
| Gene ID | 2030,63959,63997,703031,442966,101095579,510932,100055498 |
| Gene Symbol and Synonyms | 1200014D21Rik,AUG,ENT1,hENT1,mENT1,rENT1,SLC29A1 |
| Uniprot Accession | Q99808,O54698 |
| Uniprot Entry Name | S29A1_HUMAN,S29A1_RAT |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target |
| Disease | Cancer |
| Gene Ensembl | ENSG00000112759 |
| Target Classification | Tumor-associated antigen (TAA) |
The target: SLC29A1, gene name: SLC29A1, also named as ENT1. This gene is a member of the equilibrative nucleoside transporter family. The gene encodes a transmembrane glycoprotein that localizes to the plasma and mitochondrial membranes and mediates the cellular uptake of nucleosides from the surrounding medium. The protein is categorized as an equilibrative (as opposed to concentrative) transporter that is sensitive to inhibition by nitrobenzylthioinosine (NBMPR). Nucleoside transporters are required for nucleotide synthesis in cells that lack de novo nucleoside synthesis pathways, and are also necessary for the uptake of cytotoxic nucleosides used for cancer and viral chemotherapies. Multiple alternatively spliced variants, encoding the same protein, have been found for this gene. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
